Product Details

Veralfa Softgel Capsules meet British Pharmacopoeia (BP) standards for the management of calcium and bone metabolism disorders. Specifically, each softgel delivers 0.25mcg of Alfacalcidol IP in a suitable base. As a result, it offers reliable correction of calcium deficiency and metabolic bone conditions in patients with impaired vitamin D activation.

The capsules contain:

• Alfacalcidol IP (0.25mcg, in a suitable base) – A synthetic analogue of vitamin D that undergoes rapid hepatic conversion to calcitriol, the active form of vitamin D. Consequently, it increases intestinal calcium absorption and supports normal bone mineralization without requiring renal activation.

Physicians prescribe Veralfa for the management of renal osteodystrophy, hypoparathyroidism, osteoporosis, and rickets or osteomalacia, particularly in patients whose kidneys cannot adequately convert vitamin D to its active form. In addition, its oral softgel format supports simple, convenient daily dosing. Because of this profile, this product suits nephrology, endocrinology, and orthopaedic practices, as well as general physicians managing chronic calcium and bone disorders.

Key Features:

• Overall, this BP-compliant formulation guarantees pharmaceutical-grade purity
• Additionally, the softgel format supports smooth swallowing and consistent absorption
• Furthermore, each capsule delivers precise, validated dosage accuracy at 0.25mcg
• Notably, rigorous quality testing backs every stage of manufacturing
• Beyond that, blister packaging protects capsule integrity against light and moisture
• Ultimately, a reliable supply chain suits bulk distribution to hospitals, clinics, and pharmacies